不同药物在射血分数降低的心力衰竭患者治疗中的效果分析及对心室重塑指标的影响

Effect Analysis of Different Drugs in the Treatment of Heart Failure Patients with Reduced Ejection Fraction and Their Effects on Influence on Ventricular Remodeling Indexes

目的:分析不同药物在射血分数降低的心力衰竭患者治疗中的效果以及探讨其对心室重塑指标的影响。方法:选取2017年6月-2020年6月于本院就诊并进行治疗的射血分数降低的80例心力衰竭患者的临床资料进行回顾性分析。按照患者治疗药物的不同,将其分为沙库巴曲缬沙坦钠组和福辛普利组,每组40例。福辛普利组给予福辛普利钠治疗,沙库巴曲缬沙坦钠组给予沙库巴曲缬沙坦钠治疗,均连续治疗3个月。比较两组治疗效果、治疗前后的心功能指标、心室重塑指标、炎症因子水平及治疗期间不良反应发生情况。结果:沙库巴曲缬沙坦钠组治疗总有效率为95.00%高于福辛普利组的77.50%(P<0.05)。治疗后,沙库巴曲缬沙坦钠组LVEDD、LVESD均低于福辛普利组,LVEF、6 min步行距离均高于福辛普利组(P<0.05)。治疗后,沙库巴曲缬沙坦钠组IVST、LVPWT均低于福辛普利组,LVMI高于福辛普利组(P<0.05)。治疗后,沙库巴曲缬沙坦钠组IL-33、TNF-α、ICAM-1均低于福辛普利组(P<0.05)。沙库巴曲缬沙坦钠组不良反应发生率为7.50%,明显低于福辛普利组的25.00%(P<0.05)。结论:沙库巴曲缬沙坦钠治疗射血分数降低的心力衰竭患者效果较好,可有效改善患者的心功能水平,减轻炎症反应,抑制心室重塑,且安全性较高,值得临床应用。

Objective:To analyze the effects of different drugs in the treatment of patients with heart failure with reduced ejection fraction and to explore their effects on the indexes of ventricular remodeling.Method:The clinical data of 80 heart failure patients with reduced ejection fraction who received treatment in our hospital from June 2017 to June 2020 were retrospectively analyzed.According to the different treatment drugs,the patients were divided into Sacubitril Valsartan Sodium group and Fosinopril group,with 40 patients in each group.Fosinopril group was treated with Fosinopril Sodium,and Sacubitril Valsartan Sodium group was treated with Sacubitril Valsartan Sodium,all of which were treated continuously for 3 months.The treatment effect,cardiac function indexes,ventricular remodeling indexes,inflammatory cytokine levels before and after treatment and the incidence of adverse reactions were compared between the two groups.Result:The total effective rate of Sacubitril Valsartan Sodium group was 95.00%higher than 77.50%of Fosinopril group(P<0.05).After treatment,LVEDD and LVESD in Sacubitril Valsartan Sodium group were lower than those in Fosinopril group,while LVEF and 6-min walking distance in Sacubitril Valsartan Sodium group were higher than those in Fosinopril group(P<0.05).After treatment,IVST and LVPWT in Sacubitril Valsartan Sodium group were lower than those in Fosinopril group,while LVMI was higher than that in Fosinopril group(P<0.05).After treatment,IL-33,TNF-αand ICAM-1 in Sacubitril Valsartan Sodium group were lower than those in Fosinopril group(P<0.05).The incidence of adverse reactions in Sacubitril Valsartan Sodium group was 7.50%,which was significantly lower than 25.00%in Fosinopril group(P<0.05).Conclusion:Sacubitril Valsartan Sodium has a good effect in the treatment of heart failure patients with reduced ejection fraction,which can effectively improve the level of cardiac function,reduce inflammatory response and inhibit ventricular remodeling,with high safety and worthy of clinical application.